Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
Dengue virus (DENV), transmitted to humans by Aedes mosquitoes, is the aetiological agent of dengue fever and dengue haemorrhagic fever and continues to be a public health problem in the tropical and subtropical areas. However, there is currently no antiviral treatment for DENV infection. In this study, our aim was to analyze the DENV replication mechanism and obtain basic information leading to the development of new antiviral agents. As a result of analysis using infectious DENV and replicon cells, we identified some compounds that have potent anti-DENV activity and low cytotoxicity.
|